Regado Biosciences, Inc. is a biopharmaceutical company focused on the discovery and development of novel, first-in-class, actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications. Regado is pioneering the discovery and development of two-component drug systems consisting of a therapeutic aptamer and its specific active control agent. The company’s lead product candidate, REG1, is an actively controllable anticoagulant targeting coagulation Factor IXa for use in patients with a wide variety of acute coronary syndromes, or ACS, undergoing a percutaneous coronary intervention, or PCI, a hospital-based procedure used to mechanically open or widen obstructed coronary arteries. The actively controllable product candidates have the potential to improve outcomes, enhance the patient experience and reduce overall treatment costs.
View Top Employees from Regado BioSciences, Inc.Website | https://www.regadobiosciences.net |
Revenue | $17.6 million |
Funding | $43 million |
Employees | 2 (1 on RocketReach) |
Founded | 2001 |
Address | 120 Mountainview Blvd, Bernards, New Jersey 07920, US |
Phone | (919) 287-9428 |
Fax | (919) 596-8888 |
Industry | Pharmaceuticals, Biotechnology, Biotechnology Research, Healthcare, Drug Manufacturing & Research |
Competitors | Charles River Laboratories, Envigo, Premier Research, Taconic Biosciences |
SIC | SIC Code 2834 Companies, SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 32 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 325 Companies |
Looking for a particular Regado BioSciences, Inc. employee's phone or email?
The Regado BioSciences, Inc. annual revenue was $17.6 million in 2024.
Doug Brooks is the Executive Director Chemistry of Regado BioSciences, Inc..
1 people are employed at Regado BioSciences, Inc..
Regado BioSciences, Inc. is based in Bernards, New Jersey.
The NAICS codes for Regado BioSciences, Inc. are [32, 3254, 32541, 325].
The SIC codes for Regado BioSciences, Inc. are [2834, 28, 283].